A carregar...

Cardiovascular safety of fenfluramine in the treatment of Dravet syndrome: Analysis of an ongoing long‐term open‐label safety extension study

OBJECTIVE: Fenfluramine, which was previously approved as a weight loss drug, was withdrawn in 1997 when reports of cardiac valvulopathy emerged. The present study was conducted in part to characterize the cardiovascular safety profile of low‐dose fenfluramine when used in a pediatric population to...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Epilepsia
Main Authors: Lai, Wyman W., Galer, Bradley S., Wong, Pierre C., Farfel, Gail, Pringsheim, Milka, Keane, Martin G., Agarwal, Anupam
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7754414/
https://ncbi.nlm.nih.gov/pubmed/32809271
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/epi.16638
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!